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AN ANIMALS MODEL OF ALZHEIMER'S DISEASE 
CHARACTERIZATION OF NEURONAL DEGENERATION USING 
TECHNIQUE OF IMMUNOCYTOCHEMISTRY FOR 
GLIAL FIBRILLARY ACIDIC PROTEIN 
Esther Kang; Dept of Natural Science; IWU, Dr. Wayne A. Dornan 
Alzheimers disease (AD) currently affects an estimated 4 million 
Americans. Manifested initially by mild forgetfulness, this devastating 
disease eventually erodes all cognitive abilities. Neuropathologically AD is 
cnaracterized by neuritic plaques (NP) and intracellular neurofibrillary tangles 
(NFT). Although the etiology of AD is unknown, NP deposition has been 
suggested to play a fundamental role. Recently, the major component of NP 
has been identified as a B-amyloid protein that exists in an insoluble state. 
This pathology is invariably accompanied by the proliferation of adjacent gial 
cells in response to neuronal degeneration. In particular, postmortem studies 
of AD patients show a marked increase in the level of glial fibrillary acidic 
protein (GFAP) due to astrogliosis. Moreover, recent development of 
immunocytochemical techniques which stain specific proteins, have shown 
strong correlation between the degree of dementia in AD patients with the 
degree of intensity of GFAP staining. These results strongly suggests that 
immunocytochemisty for GF AP is a reliable tool in measuring 
neurodegeneration in AD patients 
In a study that is being conducted concurrently (see David Kang's 
abstract), intrahippocampal injections of Beta-Amyloid (25-35) or Ibotenic 
Acid have been used to induce a potential animal model of AD. In this study 
GFAP immunocytochemistry will be employed to assess the degree of 
neuronal degeneration in these animals.  The result of this assessment will 
be presented at the conference. 
